Envafolimab (CD274/PD-L1/B7-H1) - Onderzoeksklasse Biosimilar
Gecertificeerd

Envafolimab (CD274/PD-L1/B7-H1) - Onderzoeksklasse Biosimilar

Catalog #: 10-964
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

Envafolimab (KN035) is the first humanized anti-PD-L1 single domain antibody and new fusion protein of human IgG1 Fc. Compared with the PD-1/PD-L1 antibody that is currently on the market and under development, it has obvious advantages. . Envafolimab has the advantages of subcutaneous injection, stability at room temperature, and rapid tumor penetration, thereby improving the compliance of cancer patients with medication and improving the quality of life of patients. It is in line with the future trend of long-term management of cancer as a chronic disease.

Immunogen

Chimeric / CD274/PD-L1/B7-H1 [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Cancer, Immunology

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

(VH-CH2-CH3) 2

NCBI Organism

Homo sapiens

Other Product Names

KN-035

Beschrijving

Envafolimab (CD274/PD-L1/B7-H1) - Onderzoeksklasse Biosimilar Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamEnvafolimab (CD274/PD-L1/B7-H1) - Onderzoeksklasse Biosimilar
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer10-964